BioSpace News Archive

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical study of VAL-083

-- PTC299 is an oral therapy that has a novel dual mechanism of action that inhibits viral replication and attenuates the uncontrolled inflammatory response -- -- Stage 1 of the clinical trial is complete --

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 33 rd Annual Roth Conference , which will be held virtually on March 15-17, 2021 .

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it will be presenting at the upcoming the Diamond Equity Research Growth Invitational virtual investor conference on February 24, 2021.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2020 on Tuesday, March 2, 2021

Air Techniques, Inc., a leading innovator and manufacturer of dental equipment, will be sponsoring the course “A Practical Approach to Aerosol Mitigation,” presented by Dr. Martin Koch for the first time at the Chicago Midwinter Meeting.

OBIO® is proud to announce the success of the 2021 OBIO Investment Summit, February 9-10, 2021, which showcased the strength and opportunity in Canada’s health science industry.

Study to Bolster Clinical Performance Evidence of TAEUS® Ultrasound Device in NAFLD Patients as Commercialization Begins

Partnership aims to accelerate access to breakthrough therapies in order to combat difficult-to-treat and often drug-resistant fungal infections in Greater China SCYNEXIS will receive a $10 million upfront payment and will also be eligible to receive development and commercial milestones, plus low double-digit royalties on net product sales

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl,